<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; PhRMA</title>
	<atom:link href="http://www.tapanray.in/tag/phrma/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Why MNC Pharma Still Moans Over Indian IP Ecosystem?</title>
		<link>http://www.tapanray.in/why-mnc-pharma-still-moans-over-indian-ip-ecosystem/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=why-mnc-pharma-still-moans-over-indian-ip-ecosystem</link>
		<comments>http://www.tapanray.in/why-mnc-pharma-still-moans-over-indian-ip-ecosystem/#comments</comments>
		<pubDate>Mon, 14 May 2018 00:00:03 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2018]]></category>
		<category><![CDATA[3.d]]></category>
		<category><![CDATA[301]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Bank]]></category>
		<category><![CDATA[Chamber]]></category>
		<category><![CDATA[Cheaper]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Commerce]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[concerns]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[ecosystem]]></category>
		<category><![CDATA[expensive]]></category>
		<category><![CDATA[Form 27]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Moon]]></category>
		<category><![CDATA[multi]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Socioeconomic]]></category>
		<category><![CDATA[Special]]></category>
		<category><![CDATA[TADF]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UN]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USTR]]></category>
		<category><![CDATA[working]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9004</guid>
		<description><![CDATA[Improving patient access to expensive drugs, paving the way for entry of their cheaper generic equivalents, post patent expiry, and avoiding evergreening, is assuming priority a priority focus area in many countries. The United States is no exception, in this &#8230; <a href="http://www.tapanray.in/why-mnc-pharma-still-moans-over-indian-ip-ecosystem/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/why-mnc-pharma-still-moans-over-indian-ip-ecosystem/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Reticence Around Unveiling Clinical Trials</title>
		<link>http://www.tapanray.in/reticence-around-unveiling-clinical-trials/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=reticence-around-unveiling-clinical-trials</link>
		<comments>http://www.tapanray.in/reticence-around-unveiling-clinical-trials/#comments</comments>
		<pubDate>Mon, 17 Oct 2016 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Atorvastatin]]></category>
		<category><![CDATA[bias]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[EFPIA]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[GVK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[legalities]]></category>
		<category><![CDATA[Lipitor]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[positive]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reticence]]></category>
		<category><![CDATA[Semler]]></category>
		<category><![CDATA[statin]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[Unveiling]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7886</guid>
		<description><![CDATA[While scanning through various publications, we now get to know, almost at regular intervals, about new clinical trials capturing the newer ways of treating different ailments. Such information instils an invigorating hope in the minds of doctors and the patients &#8230; <a href="http://www.tapanray.in/reticence-around-unveiling-clinical-trials/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/reticence-around-unveiling-clinical-trials/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Arbitrary Pricing of Essential Drugs Invites State Intervention</title>
		<link>http://www.tapanray.in/arbitrary-pricing-of-essential-drugs-invites-state-intervention/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=arbitrary-pricing-of-essential-drugs-invites-state-intervention</link>
		<comments>http://www.tapanray.in/arbitrary-pricing-of-essential-drugs-invites-state-intervention/#comments</comments>
		<pubDate>Mon, 23 May 2016 00:00:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[arbitrary]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[Combiflam]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[economy]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[premium]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[winner]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7644</guid>
		<description><![CDATA[Arbitrary drug pricing has now become a subject of a raging debate, all over the globe. It involves both patented and generic drugs, as we have recently witnessed in the largest pharma market in the world – the United States. &#8230; <a href="http://www.tapanray.in/arbitrary-pricing-of-essential-drugs-invites-state-intervention/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/arbitrary-pricing-of-essential-drugs-invites-state-intervention/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘The Memory Thief’ Still Eludes Grasp Of Pharma R&amp;D</title>
		<link>http://www.tapanray.in/the-memory-thief-still-eludes-grasp-of-pharma-rd/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-memory-thief-still-eludes-grasp-of-pharma-rd</link>
		<comments>http://www.tapanray.in/the-memory-thief-still-eludes-grasp-of-pharma-rd/#comments</comments>
		<pubDate>Mon, 01 Feb 2016 00:00:17 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[ADEAR]]></category>
		<category><![CDATA[Alzheimer's]]></category>
		<category><![CDATA[brain]]></category>
		<category><![CDATA[bullet]]></category>
		<category><![CDATA[center]]></category>
		<category><![CDATA[clinic]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[eludes]]></category>
		<category><![CDATA[epidemic]]></category>
		<category><![CDATA[Failure]]></category>
		<category><![CDATA[flickers]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[grasp]]></category>
		<category><![CDATA[Hope]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inflammation]]></category>
		<category><![CDATA[magic]]></category>
		<category><![CDATA[Mayo]]></category>
		<category><![CDATA[Memory]]></category>
		<category><![CDATA[microglia]]></category>
		<category><![CDATA[MNT]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[plaque]]></category>
		<category><![CDATA[prevalence]]></category>
		<category><![CDATA[progression]]></category>
		<category><![CDATA[prowl]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[society]]></category>
		<category><![CDATA[Southhampton]]></category>
		<category><![CDATA[tangles]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tau]]></category>
		<category><![CDATA[thief]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[UCLA]]></category>
		<category><![CDATA[University]]></category>
		<category><![CDATA[‘The Memory Thief’]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7420</guid>
		<description><![CDATA[Over several decades, in fact, since its very inception, pharma R&#38;D has been playing a crucial role in alleviating diseases of various types &#8211; from severe acute infections, to a large variety of non-infectious chronic illnesses, including many dreaded diseases, &#8230; <a href="http://www.tapanray.in/the-memory-thief-still-eludes-grasp-of-pharma-rd/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-memory-thief-still-eludes-grasp-of-pharma-rd/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Patient-Centric State Initiative To Revolutionize Disease Treatment</title>
		<link>http://www.tapanray.in/a-patient-centric-state-initiative-to-revolutionize-disease-treatment/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-patient-centric-state-initiative-to-revolutionize-disease-treatment</link>
		<comments>http://www.tapanray.in/a-patient-centric-state-initiative-to-revolutionize-disease-treatment/#comments</comments>
		<pubDate>Mon, 09 Feb 2015 00:00:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2016]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[BMS]]></category>
		<category><![CDATA[Budget]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cardiovascular]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[Connect]]></category>
		<category><![CDATA[DCAT]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[genetics]]></category>
		<category><![CDATA[genome]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[NIH]]></category>
		<category><![CDATA[Obama]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Pao]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[personalized]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[Precision]]></category>
		<category><![CDATA[President]]></category>
		<category><![CDATA[Project]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Richard]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Smith]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[William]]></category>
		<category><![CDATA[‘Moonshot’ Medicine Will Let Us Down]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6374</guid>
		<description><![CDATA[In his State of the Union address, just before the recent visit to India in January 2015, President Barack Obama articulated the need to develop &#8220;Precision Medicine&#8221; in his country – a bold, giant and perhaps unprecedented State initiative to &#8230; <a href="http://www.tapanray.in/a-patient-centric-state-initiative-to-revolutionize-disease-treatment/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-patient-centric-state-initiative-to-revolutionize-disease-treatment/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New “National IPR Policy” of India – A Pharma Perspective</title>
		<link>http://www.tapanray.in/new-national-ipr-policy-of-india-a-pharma-perspective/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=new-national-ipr-policy-of-india-a-pharma-perspective</link>
		<comments>http://www.tapanray.in/new-national-ipr-policy-of-india-a-pharma-perspective/#comments</comments>
		<pubDate>Mon, 19 Jan 2015 00:00:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[301]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Congress]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Hatch]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Justice]]></category>
		<category><![CDATA[lawmakers]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[OCR]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[Orrin]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[perspective]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Prabha]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Rights]]></category>
		<category><![CDATA[Senator]]></category>
		<category><![CDATA[sofosbuvir]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Special]]></category>
		<category><![CDATA[Sridevan]]></category>
		<category><![CDATA[Tank]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Think]]></category>
		<category><![CDATA[TPF]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USTR]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6330</guid>
		<description><![CDATA[Whether under pressure or not, is hardly of any relevance now. What is relevant today is the fact that the new Indian Government, almost in a record time of just around two months, has been able to release a high &#8230; <a href="http://www.tapanray.in/new-national-ipr-policy-of-india-a-pharma-perspective/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/new-national-ipr-policy-of-india-a-pharma-perspective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Unilateral American Action on Agreed Bilateral Issues: Would India Remain Unfazed?</title>
		<link>http://www.tapanray.in/unilateral-american-action-on-agreed-bilateral-issues-would-india-remain-unfazed/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=unilateral-american-action-on-agreed-bilateral-issues-would-india-remain-unfazed</link>
		<comments>http://www.tapanray.in/unilateral-american-action-on-agreed-bilateral-issues-would-india-remain-unfazed/#comments</comments>
		<pubDate>Mon, 20 Oct 2014 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Bilateral]]></category>
		<category><![CDATA[BMS]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[cold]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[doctors without borders]]></category>
		<category><![CDATA[evergreening]]></category>
		<category><![CDATA[feet]]></category>
		<category><![CDATA[healthBig]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[List]]></category>
		<category><![CDATA[Lobby]]></category>
		<category><![CDATA[Ministry]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[MSF]]></category>
		<category><![CDATA[OCR]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[President Obama]]></category>
		<category><![CDATA[Priority]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Special 301]]></category>
		<category><![CDATA[sprycel]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[Unfazed]]></category>
		<category><![CDATA[Unilateral]]></category>
		<category><![CDATA[USTR]]></category>
		<category><![CDATA[Watch]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6128</guid>
		<description><![CDATA[I discussed in one of my earlier blog posts titled “Has Prime Minister Modi Conceded Ground To America On Patents Over Patients?” of October 6, 2014 that on April 30, 2014, the United States in its report on annual review &#8230; <a href="http://www.tapanray.in/unilateral-american-action-on-agreed-bilateral-issues-would-india-remain-unfazed/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/unilateral-american-action-on-agreed-bilateral-issues-would-india-remain-unfazed/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Leading Through The Challenge Of Change: Is Pharma Leadership Too Archaic?</title>
		<link>http://www.tapanray.in/leading-through-the-challenge-of-change-is-pharma-leadership-too-archaic/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=leading-through-the-challenge-of-change-is-pharma-leadership-too-archaic</link>
		<comments>http://www.tapanray.in/leading-through-the-challenge-of-change-is-pharma-leadership-too-archaic/#comments</comments>
		<pubDate>Mon, 16 Jun 2014 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[archaic]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[eclectic]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[inclusive]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[Michael]]></category>
		<category><![CDATA[mode]]></category>
		<category><![CDATA[Motors]]></category>
		<category><![CDATA[Ostrich]]></category>
		<category><![CDATA[owner]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[promoter]]></category>
		<category><![CDATA[prontosil]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Rsy]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Soman.]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tesla]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5512</guid>
		<description><![CDATA[A recent major global survey titled “Testing The Health Of The Pharmaceutical Industry” has revealed that a sizable majority of executives polled, though believe the sector is in good shape, are concerned of its reputation. Interestingly, 73 percent of respondents believe &#8230; <a href="http://www.tapanray.in/leading-through-the-challenge-of-change-is-pharma-leadership-too-archaic/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/leading-through-the-challenge-of-change-is-pharma-leadership-too-archaic/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The ‘TINA Factor’: A Hotspot for Patented Drugs</title>
		<link>http://www.tapanray.in/the-tina-factor-a-hotspot-for-patented-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-tina-factor-a-hotspot-for-patented-drugs</link>
		<comments>http://www.tapanray.in/the-tina-factor-a-hotspot-for-patented-drugs/#comments</comments>
		<pubDate>Mon, 16 Dec 2013 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Alternative]]></category>
		<category><![CDATA[Andre]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Dekkers]]></category>
		<category><![CDATA[factor]]></category>
		<category><![CDATA[foist]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[hepatitis]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Marijn]]></category>
		<category><![CDATA[MSF]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sofosbuvir]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[TINA]]></category>
		<category><![CDATA[TPP]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[virus]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4555</guid>
		<description><![CDATA[An article published in a global business magazine on December 5, 2013 mentioned that Marijn Dekkers, the CEO of Bayer AG reportedly has said at the Financial Times Global Pharmaceutical &#38; Biotech Conference held this month that: “Bayer didn’t develop its cancer drug, Nexavar (sorafenib) for &#8230; <a href="http://www.tapanray.in/the-tina-factor-a-hotspot-for-patented-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-tina-factor-a-hotspot-for-patented-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Big Pharma Demands Transparency, Keeping their &#8216;Black-Boxes&#8217; Tight and Safe?</title>
		<link>http://www.tapanray.in/big-pharma-demands-transparency-keeping-their-black-boxes-tight-and-safe/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=big-pharma-demands-transparency-keeping-their-black-boxes-tight-and-safe</link>
		<comments>http://www.tapanray.in/big-pharma-demands-transparency-keeping-their-black-boxes-tight-and-safe/#comments</comments>
		<pubDate>Mon, 28 Oct 2013 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[Black]]></category>
		<category><![CDATA[box]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[DTC]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[Facts]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[ghostwriting]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[governance]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[innovator]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[lobbying]]></category>
		<category><![CDATA[Making]]></category>
		<category><![CDATA[need]]></category>
		<category><![CDATA[NYT]]></category>
		<category><![CDATA[Obama]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[placebo]]></category>
		<category><![CDATA[Policies]]></category>
		<category><![CDATA[population]]></category>
		<category><![CDATA[predictable]]></category>
		<category><![CDATA[President]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[revelation]]></category>
		<category><![CDATA[safe]]></category>
		<category><![CDATA[samples]]></category>
		<category><![CDATA[secret]]></category>
		<category><![CDATA[sponsorship]]></category>
		<category><![CDATA[striking]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[tight]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[wasteful]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2780</guid>
		<description><![CDATA[Pharmaceutical Industry across the globe wants absolute transparency in all government laws, policies, guidelines, transactions and overall governance. They also expect the trade environment should be predictable, non-manipulative and business-friendly. These expectations are indeed well justified and deserve whole-hearted support &#8230; <a href="http://www.tapanray.in/big-pharma-demands-transparency-keeping-their-black-boxes-tight-and-safe/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/big-pharma-demands-transparency-keeping-their-black-boxes-tight-and-safe/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
